Fifth Disease or Erythema Infectiosum Follow-up
- Author: Kenneth T Kwon, MD; Chief Editor: Richard G Bachur, MD more...
Further Inpatient Care
- Most children with aplastic crisis require hospitalization and probable transfusion and/or IVIG therapy.
- Hospitalized patients with erythema infectiosum need no special isolation precautions; however, patients with aplastic crisis or immunosuppression with human parvovirus B19 infection should be isolated.
- Pregnant health care workers should be informed of the potential risks to the fetus from parvovirus B19 infections. They should not be involved in treatment of immunocompromised patients with chronic parvovirus infection or patients with human parvovirus B19 – associated aplastic crisis.
Further Outpatient Care
- Children with erythema infectiosum are not infectious and may attend childcare or school.
- Pregnant women in contact with patients in the incubation period of erythema infectiosum or with aplastic crisis have a relatively low potential risk of infection. They can be referred for obstetric follow-up care for possible serologic testing and close fetal monitoring.
- Routine exclusion of pregnant women from the workplace where erythema infectiosum is occurring is not recommended, due to high prevalence of human parvovirus B19 infection and low incidence of fetal effects.
Inpatient & Outpatient Medications
- Administer antipyretics, analgesics, antipruritics, and anti-inflammatories as needed.
Deterrence/Prevention
- Avoid excessive heat or sunlight, which can cause rash flare-ups.
- A vaccine is currently under development. A phase I/II clinical trial of a parvovirus B19 vaccine was completed in October 2008. Results had not been published at the time of this update.[6]
Complications
- Arthralgias/arthropathies occur in up to 10% of pediatric patients and up to 50% of adult patients.
Prognosis
- The rash of erythema infectiosum usually is self-resolving but may last several weeks or months with exacerbations from heat or sunlight.
- Arthropathy usually lasts 2-4 weeks and on rare occasions can last months to years.
- Erythroid cell line suppression usually lasts up to 2 weeks but may be chronic and last months to years.
- The onset of erythema infectiosum rash usually indicates that reticulocytosis has returned and aplastic crisis will not occur.
Patient Education
- Emphasize in discussion with parents that otherwise healthy patients with erythema infectiosum are not infectious once the rash appears; therefore, they do not need to be isolated or restricted from school/day care.
- Infected children with hemolytic disease or immunosuppression may be quite infectious. Therefore, respiratory isolation, especially from other pregnant, chronically anemic, or immunosuppressed individuals, should be observed.
- Good handwashing and infection control techniques should be encouraged.
- For excellent patient education resources, visit eMedicine's Children's Health Center. Also, see eMedicine's patient education articles Fifth Disease and Skin Rashes in Children.
Cossart YE, Field AM, Cant B, Widdows D. Parvovirus-like particles in human sera. Lancet. Jan 11 1975;1(7898):72-3. [Medline].
Anderson MJ, Higgins PG, Davis LR, Willman JS, Jones SE, Kidd IM. Experimental parvoviral infection in humans. J Infect Dis. Aug 1985;152(2):257-65. [Medline].
American Academy of Pediatrics. Red Book: 2006 Report on the Committee of Infectious Diseases. 2006:484-487.
Young NS, Brown KE. Parvovirus B19. N Engl J Med. Feb 5 2004;350(6):586-97. [Medline].
Servey JT, Reamy BV, Hodge J. Clinical presentations of parvovirus B19 infection. Am Fam Physician. Feb 1 2007;75(3):373-6. [Medline].
B-19 Parvovirus Vaccine Study. ClinicalTrials.gov. Available at http://clinicaltrials.gov/ct2/show/results/NCT00379938. Accessed 05/23/2010.
Anderson LJ. Human parvovirus. In: Richman DD, Whitley RJ, Hayden FG, eds. Clinical Virology. New York: Churchill Livingston Inc; 1997:613-31.
Cherry JD. Parvoviruses. In: Feigin RD, Cherry JD, eds. Textbook of Pediatric Infectious Diseases. Philadelphia: WB Saunders Co; 1992:1626-33.
Cohen B. Parvovirus B19: an expanding spectrum of disease. BMJ. Dec 9 1995;311(7019):1549-52. [Medline].
Feder HM Jr, Anderson I. Fifth disease. A brief review of infections in childhood, in adulthood, and pregnancy. Arch Intern Med. Oct 1989;149(10):2176-8. [Medline].
Hall CJ. Parvovirus B19 infection in pregnancy. Arch Dis Child Fetal Neonatal Ed. Jul 1994;71(1):F4-5. [Medline].
Hammond GW. Parvovirus. In: Long SS, Pickering LK, Prober CG, eds. Principles and Practice of Pediatric Infectious Diseases. New York: Churchill Livingston Inc; 1997:1205-9.
Heegaard ED, Hornsleth A. Parvovirus: the expanding spectrum of disease. Acta Paediatr. Feb 1995;84(2):109-17. [Medline].
Jones MF, Wold AD, Espy MJ, Smith TF. Serologic diagnosis of parvovirus B19 infections. Mayo Clin Proc. Nov 1993;68(11):1107-8. [Medline].
Keeler ML. Human parvovirus B-19: not just a pediatric problem. J Emerg Med. Jan-Feb 1992;10(1):39-44. [Medline].
Kirchner JT. Erythema infectiosum and other parvovirus B19 infections. Am Fam Physician. Aug 1994;50(2):335-41. [Medline].
Qari M, Qadri SM. Parvovirus B19 infection. Associated diseases, common and uncommon. Postgrad Med. Jul 1996;100(1):239-43, 246, 252. [Medline].

